Tamer Yazar1, Hülya Olgun Yazar2, Murat Cihan3. 1. Neurology, Zeytinburnu Surp Pirgıç Armenian Hospital, İstanbul, Turkey. tamer.yazar@yahoo.com.tr. 2. Neurology, Taksim Training and Research Hospital, İstanbul, Turkey. 3. Clinical Biochemist, Ordu University Training and Research Hospital, Ordu, Turkey.
Abstract
BACKGROUND AND AIMS: Neuroinflammation has a critic role in the pathophysiology of neurological diseases. The activation of microglia is the main actor in this process. The aim of this study to collect data on the role of microglial activation in the etiology, and the possible continuum at the stage of disease through the evaluation of serum galectin-3 levels in patients with Alzheimer's disease (AD). METHODS: This was a prospective and cross-sectional study conducted on patients who were diagnosed as having AD using the criteria of the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) and stages determined with the scales of Clinical Dementia Rating (CDR) and Mini-Mental State Examination (MMSE) with healthy controls. RESULTS: In our study, we studied 118 people, 57 with AD and 61 healthy people as a control group. In the AD patient group, serum galectin-3 levels were higher compared with the control group (p = 0.003). There were no significant differences in either group in other collected parameters (p > 0.05). It was observed that in all patients with AD, parallel to the stage of the disease, serum galectin-3 levels, patience's age, and duration of disease were statically and significantly increased (p < 0.05). CONCLUSION: In conclusion, serum galactin-3 levels may be associated with AD and maybe a potential biomarker for the identification of disease in the early stages. In future years, serum galectin-3 levels may become an important biomarker and therapeutic agent for chronic neurodegenerative diseases such as AD.
BACKGROUND AND AIMS: Neuroinflammation has a critic role in the pathophysiology of neurological diseases. The activation of microglia is the main actor in this process. The aim of this study to collect data on the role of microglial activation in the etiology, and the possible continuum at the stage of disease through the evaluation of serum galectin-3 levels in patients with Alzheimer's disease (AD). METHODS: This was a prospective and cross-sectional study conducted on patients who were diagnosed as having AD using the criteria of the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) and stages determined with the scales of Clinical Dementia Rating (CDR) and Mini-Mental State Examination (MMSE) with healthy controls. RESULTS: In our study, we studied 118 people, 57 with AD and 61 healthy people as a control group. In the AD patient group, serum galectin-3 levels were higher compared with the control group (p = 0.003). There were no significant differences in either group in other collected parameters (p > 0.05). It was observed that in all patients with AD, parallel to the stage of the disease, serum galectin-3 levels, patience's age, and duration of disease were statically and significantly increased (p < 0.05). CONCLUSION: In conclusion, serum galactin-3 levels may be associated with AD and maybe a potential biomarker for the identification of disease in the early stages. In future years, serum galectin-3 levels may become an important biomarker and therapeutic agent for chronic neurodegenerative diseases such as AD.
Authors: Y Jung; J L Whitwell; J R Duffy; E A Strand; M M Machulda; M L Senjem; C R Jack; V J Lowe; K A Josephs Journal: Eur J Neurol Date: 2015-06-23 Impact factor: 6.089
Authors: Antonio Boza-Serrano; Juan F Reyes; Nolwen L Rey; Hakon Leffler; Luc Bousset; Ulf Nilsson; Patrik Brundin; Jose Luis Venero; Miguel Angel Burguillos; Tomas Deierborg Journal: Acta Neuropathol Commun Date: 2014-11-12 Impact factor: 7.801
Authors: Sjoerd T T Schetters; Diego Gomez-Nicola; Juan J Garcia-Vallejo; Yvette Van Kooyk Journal: Front Immunol Date: 2018-01-25 Impact factor: 7.561
Authors: Eleazar Ramírez Hernández; Beatriz Alanis Olvera; Daniela Carmona González; Oscar Guerrero Marín; Denisse Pantoja Mercado; Lucero Valencia Gil; Luis F Hernández-Zimbrón; José Luis Sánchez Salgado; I Daniel Limón; Edgar Zenteno Journal: Glycoconj J Date: 2022-06-02 Impact factor: 3.009
Authors: Luana C Soares; Osama Al-Dalahmah; James Hillis; Christopher C Young; Isaiah Asbed; Masanori Sakaguchi; Eric O'Neill; Francis G Szele Journal: Cells Date: 2021-11-05 Impact factor: 6.600
Authors: Nataša R Mijailović; Katarina Vesic; Dragana Arsenijevic; Maja Milojević-Rakić; Milica M Borovcanin Journal: Front Cell Neurosci Date: 2022-07-05 Impact factor: 6.147
Authors: Juan García-Revilla; Antonio Boza-Serrano; Ana M Espinosa-Oliva; Manuel Sarmiento Soto; Tomas Deierborg; Rocío Ruiz; Rocío M de Pablos; Miguel Angel Burguillos; Jose L Venero Journal: Cell Death Dis Date: 2022-07-20 Impact factor: 9.685
Authors: Antonio Boza-Serrano; Agathe Vrillon; Jose Luis Venero; Kaj Blennow; Tomas Deierborg; Karolina Minta; Agnes Paulus; Lluís Camprubí-Ferrer; Megg Garcia; Ulf Andreasson; Anna Antonell; Malin Wennström; Gunnar Gouras; Julien Dumurgier; Emmanuel Cognat; Laura Molina-Porcel; Mircea Balasa; Javier Vitorica; Raquel Sánchez-Valle; Claire Paquet Journal: Acta Neuropathol Date: 2022-07-27 Impact factor: 15.887